Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Case report

Bevacizumab/crizotinib/platinum-complexes

Various toxicities, acquired drug resistance and lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Pan X, et al. A novel GHR-ALK fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report. Journal of International Medical Research 49: 1-6, No. 9, Sep 2021. Available from: URL: https://journals.sagepub.com/home/IMR Pan X, et al. A novel GHR-ALK fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report. Journal of International Medical Research 49: 1-6, No. 9, Sep 2021. Available from: URL: https://​journals.​sagepub.​com/​home/​IMR
Metadaten
Titel
Bevacizumab/crizotinib/platinum-complexes
Various toxicities, acquired drug resistance and lack of efficacy: case report
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-15004-y

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Tozinameran

Case report

Gefitinib

Case report

Multiple drugs

Case report

Pazopanib